ALK and inflammatory myofibroblastic tumor: Recent studies have shown that ALK-negative IMT may harbor other kinase fusions such as ROS1, NTRK, RET or PDGFR beta, giving rise to genome-level research into potential tumorigenic drivers (of this IMT subset).